


Curriculum Vitae

Name	Jedd D. Wolchok, MD, PhD, FASCO	
Current Position & Affiliation	Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation Chief, Immuno-Oncology Service, Human Oncology and Pathogenesis Program Director, Parker Institute for Cancer Immunotherapy at MSK Associate Director, Ludwig Center for Cancer Immunotherapy, Member, Ludwig Cancer Research Professor of Medicine, Weill Medical College of Cornell University	
Country	USA	

Educational Background

Degree	Institution Name and Location	Dates attended	Year Awarded
BA	Princeton University Princeton, NJ	9/1984-5/1987	1987
MS	New York University (Graduate School of Arts and Science) New York, NY	8/1989-5/1993	1991
PhD	New York University (Graduate School of Arts and Science) New York, NY	8/1989-5/1993	1993
MD	New York University School of Medicine New York, NY	8/1987-5/1994	1994

Professional Experience

Title	Institution name and location	Dates held
Clinical Assistant	Memorial Sloan Kettering Cancer Center, NY	July 1, 2000- June 30,

Instructor in Medicine	Weill Medical College of Cornell University, NY	July 1, 2000- June 30, 2004
Assistant Member	Memorial Sloan Kettering Cancer Center, NY	July 1, 2004- June 30, 2008
Assistant Professor of Medicine	Weill Medical College of Cornell University, NY	July 1, 2004- June 30, 2008
Associate Member	Memorial Sloan Kettering Cancer Center, NY	July 1, 2008- June 30, 2014
Joint Appointee, SKI	Immunology Program, Sloan Kettering Institute Memorial Sloan Kettering	July 1, 2008- Present
Associate Member	Ludwig Institute for Cancer Research Ltd., New York, NY	July 1, 2009- Present
Associate Professor of Medicine	Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences of Cornell University	July 1, 2009- Present
Associate Physician	The Rockefeller University Hospital, NY	July 1, 2010- June 30, 2013
Associate Attending Physician	The Rockefeller University Hospital, NY	July 1, 2013- Present
Professor of Medicine	Weill Medical College of Cornell University, NY	July 1, 2014- Present
Service Chief	Melanoma and Immunotherapeutics Service, NY	July 1, 2014- Oct 3, 2019
Service Chief	Immuno-Oncology Service, HOPP	Sept 24, 2019- Present

Professional Organizations

Memorial Sloan Kettering Cancer Center

Main Scientific Publications

1. **Wolchok, J.D.** et al. (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 15(23):7412-20. PMID: 19934295.

2. Hodi, F.S. et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med.* 363(8):711-23. PMID: PMC3549297.
3. Hirschhorn-Cymerman D, Budhu S, Kitano S, Liu C, Zhao F, Zhong H, Lesokhin AM, Avogadri-Connors F, Yuan J, Li Y, Houghton AN, Merghoub T, **Wolchok JD.**(2012) Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. *J Exp Med.* 209(11):2113-26. PMID: PMC3478933.
4. Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Jr., Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, **Wolchok JD.** Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *New England Journal of Medicine* 2011; 364(26):2517-26.
5. **Wolchok JD,** Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon R, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. Nivolumab (Anti-PD-1) plus Ipilimumab (Anti-CTLA-4) in Advanced Melanoma. *N Engl J Med.* 2013 Jul 11;369(2):122-33.
6. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, **Wolchok JD.** Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma *N Engl J Med.* 2015 Jul 2;373(1):23-34.
7. **Wolchok JD,** Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbe C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *The New England journal of medicine* 2017;377:1345-56.
8. De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, Budhu S, Ghosh A, Pink M, Tchaicha J, Douglas M, Tibbitts T, Sharma S, Proctor J, Kosmider N, White K, Stern H, Soglia J, Adams J, Palombella VJ, McGovern K, Kutok JL, **Wolchok JD,** Merghoub T.(2016) Overcoming resistance to checkpoint blockade therapy by targeting PI3K γ in myeloid cells. *Nature.* 539(7629):443-7. PMID: PMC5634331.
9. Khalil DN, Suek N, Campesato LF, Budhu S, Redmond D, Samstein RM, Krishna C, Panageas KS, Capanu M, Houghton S, Hirschhorn D, Zappasodi R, Giese R, Gasmi B, Schneider M, Gupta A, Harding JJ, Moral JA, Balachandran VP, **Wolchok JD,** Merghoub T. In situ vaccination with defined factors overcomes T cell exhaustion in

distant tumors. *The Journal of clinical investigation* 2019;129:3435-47.

10. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Marquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schoffski P, Carlino MS, Lebbe C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JJ, Balogh A, Moshyk A, Hodi FS, **Wolchok JD**. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *The New England journal of medicine* 2019;381:1535-46.

11. Zappasodi R, Sirard C, Li Y, Budhu S, Abu-Akeel M, Liu C, Yang X, Zhong H, Newman W, Qi J, Wong P, Schaer D, Koon H, Velcheti V, Hellmann MD, Postow MA, Callahan MK, **Wolchok JD**, Merghoub T.(2019) Rational design of anti-GITR-based combination immunotherapy. *Nature medicine*. 25(5):759-66. PMID: PMC7457830.

12. Campesato LF, Budhu S, Tchaicha J, Weng CH, Gigoux M, Cohen IJ, Redmond D, Mangarin L, Pourpe S, Liu C, Zappasodi R, Zamarin D, Cavanaugh J, Castro AC, Manfredi MG, McGovern K, Merghoub T, **Wolchok JD**. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. *Nat Commun* 2020;11:4011

13. Zappasodi R, Serganova I, Cohen I, Maeda M, Shindo M, Senbabaoglu Y, Watson MJ, Leftin A, Maniyar R, Verma S, Lubin M, Ko M, Mane MM, Zhong H, Liu C, Ghosh A, Abu-Akeel M, Ackerstaff E, Koutcher JA, Ho PC, Delgoffe GM, Blasberg R, **Wolchok JD** and Merghoub T. CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumors. *Nature* 2021, *Nature* 2021 Feb 15.